CN101610768B - 抑制c kit激酶的方法 - Google Patents
抑制c kit激酶的方法 Download PDFInfo
- Publication number
- CN101610768B CN101610768B CN2007800231790A CN200780023179A CN101610768B CN 101610768 B CN101610768 B CN 101610768B CN 2007800231790 A CN2007800231790 A CN 2007800231790A CN 200780023179 A CN200780023179 A CN 200780023179A CN 101610768 B CN101610768 B CN 101610768B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- cyano
- mmol
- carboxylic acid
- imidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C1)=CCN(C)C1(O)O* Chemical compound CC(C1)=CCN(C)C1(O)O* 0.000 description 16
- QWLOHEYXJJBMSN-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c(cc1)cc(C2=CCCCC2)c1NC(c1n[n](COCC[Si](C)(C)C)cn1)=O)=N Chemical compound CC(C)(C)OC(N(CC1)CCC1c(cc1)cc(C2=CCCCC2)c1NC(c1n[n](COCC[Si](C)(C)C)cn1)=O)=N QWLOHEYXJJBMSN-UHFFFAOYSA-N 0.000 description 1
- BHEZRLRYVAVOAI-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c(cc1)nc(C2=CCC(C)(C)CC2)c1N)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1c(cc1)nc(C2=CCC(C)(C)CC2)c1N)=O BHEZRLRYVAVOAI-UHFFFAOYSA-N 0.000 description 1
- ASKPWELCGCGAEW-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c(nc1C2=CCC(C)(C)CC2)ccc1NC(c1nc(C#N)c[n]1COCC[Si+](C)(C)C)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1c(nc1C2=CCC(C)(C)CC2)ccc1NC(c1nc(C#N)c[n]1COCC[Si+](C)(C)C)=O)=O ASKPWELCGCGAEW-UHFFFAOYSA-N 0.000 description 1
- WIBGKIDZKILOHV-UHFFFAOYSA-N CC(N(CC1)CCC1c(cc1C2=CCCNC2)ccc1NC(c1nc(C#N)c[nH]1)=O)=C Chemical compound CC(N(CC1)CCC1c(cc1C2=CCCNC2)ccc1NC(c1nc(C#N)c[nH]1)=O)=C WIBGKIDZKILOHV-UHFFFAOYSA-N 0.000 description 1
- VMQQKIHPNCRHLF-UHFFFAOYSA-N CNC(CN(C)C1)N(C)C1O Chemical compound CNC(CN(C)C1)N(C)C1O VMQQKIHPNCRHLF-UHFFFAOYSA-N 0.000 description 1
- SPZDCHRXPBSIHM-UHFFFAOYSA-N CS(CCN(CC1)CCC1c(cc1C2=CCCCC2)ccc1NC(c1nc(C#N)c[nH]1)=O)(=O)=O Chemical compound CS(CCN(CC1)CCC1c(cc1C2=CCCCC2)ccc1NC(c1nc(C#N)c[nH]1)=O)(=O)=O SPZDCHRXPBSIHM-UHFFFAOYSA-N 0.000 description 1
- UNYBEVJTVJTIAO-UHFFFAOYSA-N Cc1c[nH]c(C(Nc(ccc(C(CC2)CCN2C(CN)=O)c2)c2C2=CCCCC2)=O)n1 Chemical compound Cc1c[nH]c(C(Nc(ccc(C(CC2)CCN2C(CN)=O)c2)c2C2=CCCCC2)=O)n1 UNYBEVJTVJTIAO-UHFFFAOYSA-N 0.000 description 1
- ROGPQKPWXCGIHH-UHFFFAOYSA-N N#Cc1c[nH]c(C(Nc2ccc(C(CC3)CCS3(=O)=O)cc2C2=CCCCC2)=O)n1 Chemical compound N#Cc1c[nH]c(C(Nc2ccc(C(CC3)CCS3(=O)=O)cc2C2=CCCCC2)=O)n1 ROGPQKPWXCGIHH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210022810.8A CN102670605B (zh) | 2006-04-20 | 2007-04-19 | 抑制c kit激酶的方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79347106P | 2006-04-20 | 2006-04-20 | |
| US60/793,471 | 2006-04-20 | ||
| PCT/US2007/066985 WO2007124369A2 (en) | 2006-04-20 | 2007-04-19 | Method of inhibiting c kit kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210022810.8A Division CN102670605B (zh) | 2006-04-20 | 2007-04-19 | 抑制c kit激酶的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101610768A CN101610768A (zh) | 2009-12-23 |
| CN101610768B true CN101610768B (zh) | 2012-03-21 |
Family
ID=38625740
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800231790A Expired - Fee Related CN101610768B (zh) | 2006-04-20 | 2007-04-19 | 抑制c kit激酶的方法 |
| CN201210022810.8A Expired - Fee Related CN102670605B (zh) | 2006-04-20 | 2007-04-19 | 抑制c kit激酶的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210022810.8A Expired - Fee Related CN102670605B (zh) | 2006-04-20 | 2007-04-19 | 抑制c kit激酶的方法 |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP2015748B1 (enExample) |
| JP (1) | JP5595727B2 (enExample) |
| KR (1) | KR101448052B1 (enExample) |
| CN (2) | CN101610768B (enExample) |
| AU (1) | AU2007240400B2 (enExample) |
| BR (1) | BRPI0710542B8 (enExample) |
| CA (1) | CA2649755C (enExample) |
| CO (1) | CO6382175A2 (enExample) |
| CR (1) | CR10450A (enExample) |
| EA (1) | EA016611B1 (enExample) |
| EC (1) | ECSP088842A (enExample) |
| ES (2) | ES2389678T3 (enExample) |
| GT (1) | GT200800225A (enExample) |
| IL (1) | IL194846A (enExample) |
| MX (1) | MX2008013528A (enExample) |
| MY (1) | MY147226A (enExample) |
| NO (1) | NO342001B1 (enExample) |
| NZ (1) | NZ572200A (enExample) |
| SG (1) | SG171592A1 (enExample) |
| WO (1) | WO2007124369A2 (enExample) |
| ZA (1) | ZA200809874B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| CN104370880A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类蛋白酶抑制剂及其制备方法和用途 |
| ES2671323T3 (es) | 2013-07-22 | 2018-06-06 | Idorsia Pharmaceuticals Ltd | Derivados 1¿(piperazin¿1¿il)¿2¿([1,2,4]triazol¿1¿il)¿etanona |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| PL3245203T3 (pl) | 2015-01-15 | 2019-05-31 | Idorsia Pharmaceuticals Ltd | Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3 |
| CN105753770A (zh) * | 2015-05-27 | 2016-07-13 | 上海佐林生物医药有限公司 | 蛋白激酶抑制剂制备方法、中间体、制备方法及应用 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1414858A (zh) * | 1999-12-27 | 2003-04-30 | 诺瓦提斯公司 | 受体酪氨酸激酶抑制剂和可与α1－酸性糖蛋白结合的有机化合物的联合形式 |
| WO2005047273A1 (en) * | 2003-11-14 | 2005-05-26 | Novartis Ag | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors |
| CN1684959A (zh) * | 2002-08-02 | 2005-10-19 | Ab科学公司 | 2－(3－氨基芳基)氨基－4－芳基－噻唑及其作为c－kit抑制剂的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| CA2372053C (en) | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DK1684750T3 (da) * | 2003-10-23 | 2010-08-09 | Ab Science | 2-aminoaryloxazol-forbindelser som tyrosinkinase-inhibitorer |
| CA2554925A1 (en) * | 2004-01-30 | 2005-08-11 | Ab Science | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
| JP5046950B2 (ja) * | 2004-10-22 | 2012-10-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃ−ｆｍｓキナーゼのインヒビター |
| US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| JP2009511628A (ja) * | 2005-10-18 | 2009-03-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｆｌｔ３キナーゼの阻害方法 |
| WO2007124322A1 (en) * | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| AU2006342509A1 (en) * | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica, N.V. | c-fms kinase inhibitors |
| SI2021335T1 (sl) * | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Heterocikliäśne spojine kot zaviralci c-fms kinaze |
-
2007
- 2007-04-19 SG SG201102829-7A patent/SG171592A1/en unknown
- 2007-04-19 EP EP07760927A patent/EP2015748B1/en active Active
- 2007-04-19 AU AU2007240400A patent/AU2007240400B2/en not_active Ceased
- 2007-04-19 ES ES07760927T patent/ES2389678T3/es active Active
- 2007-04-19 EA EA200870454A patent/EA016611B1/ru unknown
- 2007-04-19 JP JP2009506778A patent/JP5595727B2/ja not_active Expired - Fee Related
- 2007-04-19 KR KR1020087028216A patent/KR101448052B1/ko not_active Expired - Fee Related
- 2007-04-19 MX MX2008013528A patent/MX2008013528A/es active IP Right Grant
- 2007-04-19 BR BRPI0710542A patent/BRPI0710542B8/pt not_active IP Right Cessation
- 2007-04-19 WO PCT/US2007/066985 patent/WO2007124369A2/en not_active Ceased
- 2007-04-19 NZ NZ572200A patent/NZ572200A/en not_active IP Right Cessation
- 2007-04-19 EP EP11161399.8A patent/EP2397138B1/en active Active
- 2007-04-19 CN CN2007800231790A patent/CN101610768B/zh not_active Expired - Fee Related
- 2007-04-19 CA CA2649755A patent/CA2649755C/en active Active
- 2007-04-19 ES ES11161399.8T patent/ES2458291T3/es active Active
- 2007-04-19 CN CN201210022810.8A patent/CN102670605B/zh not_active Expired - Fee Related
-
2008
- 2008-10-20 MY MYPI20084185A patent/MY147226A/en unknown
- 2008-10-21 GT GT200800225A patent/GT200800225A/es unknown
- 2008-10-22 EC EC2008008842A patent/ECSP088842A/es unknown
- 2008-10-22 IL IL194846A patent/IL194846A/en active IP Right Grant
- 2008-10-24 CO CO08113911A patent/CO6382175A2/es active IP Right Grant
- 2008-11-19 ZA ZA2008/09874A patent/ZA200809874B/en unknown
- 2008-11-20 CR CR10450A patent/CR10450A/es unknown
- 2008-11-20 NO NO20084892A patent/NO342001B1/no not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1414858A (zh) * | 1999-12-27 | 2003-04-30 | 诺瓦提斯公司 | 受体酪氨酸激酶抑制剂和可与α1－酸性糖蛋白结合的有机化合物的联合形式 |
| CN1684959A (zh) * | 2002-08-02 | 2005-10-19 | Ab科学公司 | 2－(3－氨基芳基)氨基－4－芳基－噻唑及其作为c－kit抑制剂的应用 |
| WO2005047273A1 (en) * | 2003-11-14 | 2005-05-26 | Novartis Ag | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101340909B (zh) | 抑制flt3激酶的方法 | |
| CN101610768B (zh) | 抑制c kit激酶的方法 | |
| CN101437514B (zh) | C-fms激酶抑制剂 | |
| US9526731B2 (en) | Method of inhibiting C-KIT kinase | |
| CN101917994A (zh) | Cfms抑制剂用于治疗或预防骨癌以及与骨癌相关的骨丢失和骨痛的用途 | |
| CN105246890A (zh) | 吡咯并[2,3-b]吡啶cdk9激酶抑制剂 | |
| CN117730080A (zh) | 吡啶并嘧啶酮类衍生物及其制备方法和用途 | |
| HK1124766B (en) | A c-kit kinase inhibitor for use in the treatment of gastrointestinal stromal tumor or mastocytosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120321 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |